About Tafasitamab
Tafasitamab is a prescribed medicine for the treatment of Lenalidomide and the CD19-directed cytolytic antibody Tafasitamab is recommended for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that has relapsed or become resistant, including DLBCL resulting from low-grade lymphoma, and who are not candidates for autologous stem cell transplant (ASCT).
Based on the total response rate, this indication is granted under rapid approval. Continued clearance for this indication might be reliant on confirmatory trials demonstrating and describing the clinical benefit.
Strength
200 mg; single dose vial
Recommended Dosage
The recommended dosage of Tafasitamab is 12 mg/kg as an intravenous infusion.
Important: If patients experience any adverse reactions from the Tafasitamab treatment, it is necessary to consult the treating doctor.
Warnings & Precautions
Common Tafasitamab Side Effects
Storage and Handling
In a carton, each 200 mg vial is separately packed.
Keep chilled at 2 to 8 °C in the original carton to avoid light exposure. Do not tremble.
Avoid freezing.
We follow a four-step process to procure the medicines:
When importing medication, we will need the following documents from the patient:
Once we have all these documents, the Sansfro team will initiate the application process for an import license. This license is essential to ensure that we can obtain the necessary medication once it receives government approval.
No news found.
Sansfro is committed to bridging the healthcare gap. Our purpose is to bring hope and healing to patients suffering from rare diseases by linking them with life-saving treatments through our Named Patient Program. Join us in our quest for a better and healthier world.
Know More...What kinds of cancer does Monjuvi treat?
A: To treat people with diffuse large B-cell lymphoma (DLBCL), a kind of non-Hodgkin lymphoma, which has relapsed or is refractory, Monjuvi is combined with lenalidomide.
How does Monjuvi function?
A specific protein called CD19 that is present on the surface of malignant B-cells is the target and the binding site for the drug Monjuvi. Monjuvi aids the immune system in identifying and combating cancer cells, preventing their proliferation, by attaching to CD19.
How to administer Tafasitamab?
Monjuvi is administered by a healthcare practitioner by intravenous (IV) infusion. The first infusion is often administered over many hours, with successive infusions being shorter depending on the patient’s tolerance.
What is the recommended dosage of Tafasitamab?
Monjuvi of Tafasitamab dose is determined by factors such as the patient’s weight and medical condition. It is typically used in conjunction with lenalidomide. A qualified healthcare professional should establish a dosage schedule for the patient.
What are the common Monjuvi side effects?
Fatigue, diarrhea, fever, cough, nausea, headache, and low levels of particular blood cells are all common adverse effects of Monjuvi. More significant side effects are possible, therefore patients should discuss potential concerns with their doctor.
Is Monjuvi appropriate for all DLBCL patients?
Monjuvi or Tafasitamab is indicated for patients with relapsed or refractory DLBCL who are not candidates for autologous stem cell transplant and have not responded to earlier treatment choices.
What should I discuss with my doctor before beginning Tafasitamab treatment?
It is necessary to discuss the medical history, current medicines, allergies, and any other health issues with the treating doctor before beginning Monjuvi treatment. This will assist the patient in determining whether Monjuvi is a safe and acceptable treatment for the patient.
What is the price of the Monjuvi in India?
Monjuvi price in India depends on the product requirement. Request more details by reaching out to our Patient Support Team at (+91) 93157 05373 or help@sansfro.com
Medical counselor
India, Andorra, Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe, Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, etc.